Resistance acquisition to MDM2 inhibitors
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Various experimental strategies aim to (re)activate p53 signalling in cancer cells. The most advanced clinically are small-molecule inhibitors of the autoregulatory interaction between p53 and MDM2 (murine double minute 2). Different MDM2 inhibitors are currently under investigation in clinical trials. As for other targeted anti-cancer therapy approaches, relatively rapid resistance acquisition may limit the clinical efficacy of MDM2 inhibitors. In particular, MDM2 inhibitors were shown to induce p53 mutations in experimental systems. In the present article, we summarize what is known about MDM2 inhibitors as anti-cancer drugs with a focus on the acquisition of resistance to these compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is important to note, that, because of the nature of GBM tumor vasculature, which was shown to comprise between 30–50% of poorly perfused vessels [35], we cannot exclude the possibility of a contribution from intravascular drug and blood in our brain tissue AUCs calculations.”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [35]
In the citing paper
“Of note, acquired TP53 mutation is a key mechanism of resistance to MDM2 inhibition in vitro.31”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [31]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 407
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395
Cited by
p53 Family and Cellular Stress Responses in Cancer
Pflaum, J., Schlosser, S., & Müller, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 291
The role of DNA damage responses in p53 biology
Speidel, D. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1459-z · Cited by 160
Self-citationVerreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Deng, M., Zhang, L., Zheng, W., Chen, J., Du, N., Li, M., Chen, W., Huang, Y., Zeng, N., Song, Y., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02586-w · Cited by 118
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106
Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells
Michaelis, M., Selt, F., Rothweiler, F., Löschmann, N., Nüsse, B., Dirks, W. G., Zehner, R., & Cinatl, J. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108758 · Cited by 52
Self-citationDrug-adapted cancer cell lines as preclinical models of acquired resistance
Michaelis, M., Wass, M. N., & Cinatl, J. J. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.005 · Cited by 61
Self-citationGoncearenco, A., Li, M., Simonetti, F. L., Shoemaker, B. A., & Panchenko, A. R. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7201-2_15 · Cited by 41
Gomes, S., Raimundo, L., Soares, J., Loureiro, J. B., Leão, M., Ramos, H., Monteiro, M. N., Lemos, A., Moreira, J., Pinto, M. M. M., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.014 · Cited by 39
YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway
Tong, H., Zhao, K., Zhang, J., Zhu, J., & Xiao, J. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s185514 · Cited by 42
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
Iyer, S. V., Parrales, A., Begani, P., Narkar, A., Adhikari, A. S., Martinez, L. A., & Iwakuma, T. (2016) · Oncotarget · doi:10.18632/oncotarget.6634 · Cited by 28
MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)
Rusiecki, R., Witkowski, J., & Jaszczewska‐Adamczak, J. A. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666191022163540 · Cited by 30
Azme, E., Hasan, M. M., Ali, M. L., Alam, R., Hoque, N., Noushin, F., Kabir, M. F., Islam, M. A., Nipun, T. S., Hossen, S. M. M., et al. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1527008 · Cited by 32
Cheng, X., Chen, R., Zhou, T., Zhang, B., Li, Z., Gao, M., Huang, Y., Liu, H., & Su, Z. (2022) · Nature Communications · doi:10.1038/s41467-022-28721-x · Cited by 24
Luo, H., Si, D., Sun, X.-J., Wang, M., Yang, Y.-B., Wang, B., Wen, H., Li, W., & Li, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115282 · Cited by 17
Thayer, K. M., & Beyer, G. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147806 · Cited by 10
Witkowski, J., Polak, S., Rogulski, Z., & Pawelec, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112984 · Cited by 11
Michaelis, M., Schneider, C., Rothweiler, F., Rothenburger, T., Mernberger, M., Nist, A., von Deimling, A., Speidel, D., Stiewe, T., & Cinatl, J. J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/404475 · Cited by 7
Self-citationQin, L., Liu, H., Chen, R., Zhou, J., Cheng, X., Chen, Y., Huang, Y., & Su, Z. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00903 · Cited by 7
Zhang, X., Zhou, C., Yang, Y., Liu, H., Wang, S., Ding, X., & Hu, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202100517 · Cited by 5
Peptide and protein chemistry approaches to study the tumor suppressor protein p53
Chatterjee, C., & Singh, S. K. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob00902a · Cited by 4
Bechill, J., Zhong, R., Zhang, C., Solomaha, E., & Spiotto, M. T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154125 · Cited by 4
Protein–Protein Interaction Inhibitors in Cancer
Hardcastle, I. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12392-3 · Cited by 5
Self-citationProtein–Protein Interaction Inhibitors
Hardcastle, I. R. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_27 · Cited by 4
Self-citationVaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0244 · Cited by 2
Aptullahoğlu, E., & Kaygusuz, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178648 · Cited by 1
Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf259
Deng, M., Zhang, L., Zheng, W., Chen, J., Du, N., Li, M., Chen, W., Huang, Y., Zeng, N., Song, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606688
Improving neuroblastoma therapy with a new p53 family-activating agent
Almeida, J., Resende, D. I. S. P., da Silva, R. D. F., Villasante, A., Murphy, C., Zingales, V., Palmeira, A., Škoda, J., Broso, F., Vadivellu, A., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178295
Deng, M., Zhang, L., Zheng, W., Chen, J., Du, N., Li, M., Chen, W., Huang, Y., Zeng, N., Song, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606685
Metadata
- Authors
- Cinatl, J., Speidel, D., Hardcastle, I., & Michaelis, M.
- Affiliations
- Goethe University Frankfurt (DE)
- The University of Sydney (AU)
- Newcastle University (GB)
- University of Kent (GB)
- Corresponding author
- Cinatl, Jindrich
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2014-08-01
- Volume
- 42
- Issue
- 4
- Pages
- 752-757
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2062745242
- Cited by
- 30
- References
- 50
- Citations by year
- 2025: 5 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 3 · 2014: 2
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Biochemical Society Transactions (publishedVersion)
- PubMed (publishedVersion)
- Kent Academic Repository (University of Kent) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- MDM2 inhibitors, drug resistance, p53, p53-MDM2 interaction, TP53 mutation, small molecule inhibitors, cancer therapy, targeted therapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Signal Transduction, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.